title: Nanosuspension based in situ gelling nasal spray of carvedilol: development, in vitro and in vivo characterization.
abstract: The objective of the present investigation was to develop in situ gelling nasal spray formulation of carvedilol (CRV) nanosuspension to improve the bioavailability and therapeutic efficiency. Solvent precipitation-ultrasonication method was opted for the preparation of CRV nanosuspension which further incorporated into the in situ gelling polymer phase. Optimized formulation was extensively characterized for various physical parameters like in situ gelation, rheological properties and in vitro drug release. Formation of in situ gel upon contact with nasal fluid was conferred via the use of ion-activated gellan gum as carrier. In vivo studies in rabbits were performed comparing the nasal bioavailability of CRV after oral, nasal, and intravenous administration. Optimized CRV nanosuspension prepared by combination of poloxamer 407 and oleic acid showed good particle size [d (0.9); 0.19 μm], zeta potential (+10.2 mV) and polydispersity (span; 0.63). The formulation containing 0.5% w/v gellan gum demonstrated good gelation ability and desired sustained drug release over period of 12 h. In vivo pharmacokinetic study revealed that the absolute bioavailability of in situ nasal spray formulation (69.38%) was significantly increased as compared to orally administered CRV (25.96%) with mean residence time 8.65 h. Hence, such in situ gel system containing drug nanosuspension is a promising approach for the intranasal delivery in order to increase nasal mucosal permeability and in vivo residence time which altogether improves drug bioavailability.
authors.affiliation: Center for Novel Drug Delivery Systems, Department of Pharmaceutical Sciences and Technology, Institute of Chemical Technology, N. P. Marg, Matunga (E), Mumbai, 400019, India.
authors.forename: Nilesh S
authors.initials: NS
authors.lastname: Saindane
authors.forename: Kunal P
authors.initials: KP
authors.lastname: Pagar
authors.forename: Pradeep R
authors.initials: PR
authors.lastname: Vavia
mesh_terms: D000281:Administration, Intranasal; D018674:Adrenergic Antagonists / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000818:Animals; D000959:Antihypertensive Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001682:Biological Availability; D002152:Calorimetry, Differential Scanning; D002227:Carbazoles / Q000008:administration & dosage* / Q000493:pharmacokinetics; D000077261:Carvedilol; D005260:Female; D005782:Gels; D066298:In Vitro Techniques; D008297:Male; D008855:Microscopy, Electron, Scanning; D053758:Nanoparticles; D033362:Powder Diffraction; D011412:Propanolamines / Q000008:administration & dosage* / Q000493:pharmacokinetics; D011817:Rabbits; D014783:Viscosity
chemical_list: D018674:Adrenergic Antagonists; D000959:Antihypertensive Agents; D002227:Carbazoles; D005782:Gels; D011412:Propanolamines; D000077261:Carvedilol